Welcome to
Endpoints News’
manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Michigan-based manufacturer Hans Scien
tific is investing
$2 billion
in the US due to President Donald Trump’s
threat last Thursday
of 100% pharma tariffs. The expansion includes seven already-planned new builds, with one of the sites already completed, the company said in a Tuesday press release.
Thermo Fisher Scientific and Vaxcyt
e have
inked
a commercial manufacturing deal worth up to $1 billion, the companies said Tuesday. Thermo Fisher will provide fill-finish commercial production for Vaxcyte’s pneumococcal conjugate vaccines at its site in Greenville, NC.
Bristol Myers Squib
b
has
sold
its manufacturing facility in Phoenix to Rois Phoenix, a subsidiary of Rovi Pharma Industrial Services, according to a Monday release. Rois will continue to manufacture products for BMS at the factory for the next five years, receiving $50 million each year from the drugmaker. The transaction is expected to close in the first half of 2026.
Mesoblast has
confirmed
that its allogeneic cell therapy products will not be subject to the Trump administration’s 100% tariffs on branded drugs since its products are manufactured from US donors, according to a Wednesday release.
Rezon Bio has
rebranded
as a new biologics CDMO, with facilities in Gdańsk and Duchnice, Poland, the company said Monday. The company had been a biosimilar manufacturer.
Siegfried’s subsidiary Dinamiqs has
opened
a new viral vector manufacturing factory in Zurich, according to a Monday release. Dinamiqs has also inked a deal with Seal Therapeutics to make its gene therapy for a severe form of muscular dystrophy.
Australian CDMO Cell Therapies has
signed
a
memorandum of understanding with Japan-based Teijin to improve the manufacturing and accessibility of cell and gene therapies in Japan and Australia, according to a Wednesday release. The partnership will expand CGT production capacity and provide tech transfers to sites across the Asia-Pacific region.
Afton Scientific has broken ground
on a
$200 million
expansion of its manufacturing facility in Charlottesville, VA. The site is expected to generate 200 new jobs, according to a Tuesday announcement.
Symbiosis Pharma has
completed
qualification of its fill-finish manufacturing line at its facility in Stirling, Scotland, the company said Tuesday.
CDMO PolyPeptide is
expanding
capacity
at its facility in Braine-l’Alleud, Belgium, backed by customer funding, the company said Monday.
Cell therapy CDMO Made Scientific
has
partnered
with Syenex to improve T cell therapy production, according to a Tuesday release. Syenex will provide its engineering platforms to Made Scientific, which can incorporate the platforms into its manufacturing processes.
Dr. Reddy’s Laboratories
has been
handed
a Form 483 by the FDA after an inspection of its site in the Medchal-Malkajgiri district in India between Sept. 4 and Sept. 12. The seven-page letter, which was published Wednesday, outlined five observations, including failure to prevent microbiological contamination of its products and inadequate risk assessment to avoid cross-contamination.
